--- title: "Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Update" type: "News" locale: "en" url: "https://longbridge.com/en/news/292407283.md" description: "Fresenius SE & Co. (FSNUY) saw a significant 375.6% increase in short interest to 282,012 shares as of June 30. The stock rose $0.06 to $12.18 on Friday with lower-than-average volume. Recent quarterly earnings missed estimates, reporting $0.24 EPS against $0.25 expected. Despite this, Morgan Stanley restated an 'overweight' rating, and the consensus remains 'Buy'. Key financial metrics include a market cap of $27.44 billion and a P/E ratio of 16.24." datetime: "2026-07-12T17:00:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292407283.md) - [en](https://longbridge.com/en/news/292407283.md) - [zh-HK](https://longbridge.com/zh-HK/news/292407283.md) --- # Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Update Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) was the target of a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 282,012 shares, an increase of 375.6% from the June 15th total of 59,293 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 392,720 shares, the short-interest ratio is presently 0.7 days. Get **Fresenius SE & Co.** alerts: ## Fresenius SE & Co. Price Performance Shares of FSNUY stock traded up $0.06 during trading hours on Friday, hitting $12.18. 78,030 shares of the company's stock were exchanged, compared to its average volume of 221,486. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.41. The firm has a market cap of $27.44 billion, a P/E ratio of 16.24 and a beta of 0.63. The firm has a 50 day moving average of $11.42 and a two-hundred day moving average of $13.02. Fresenius SE & Co. has a fifty-two week low of $10.33 and a fifty-two week high of $33.93. Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.25 by ($0.01). The company had revenue of $6.75 billion during the quarter, compared to analyst estimates of $6.79 billion. Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.09%. Sell-side analysts forecast that Fresenius SE & Co. will post 1.03 EPS for the current year. ## Analyst Upgrades and Downgrades Separately, Morgan Stanley restated an "overweight" rating on shares of Fresenius SE & Co. in a research report on Tuesday, June 23rd. Three analysts have rated the stock with a Buy rating, According to MarketBeat, Fresenius SE & Co. currently has a consensus rating of "Buy". **Get Our Latest Analysis on FSNUY** ## About Fresenius SE & Co. (Get Free Report) Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world's leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella. The company operates through four main business segments. ## Featured Stories - Five stocks we like better than Fresenius SE & Co. - 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk - Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs - Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing - This Dividend ETF Choice Could Shape Your Income Strategy Through 2026 _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Fresenius SE & Co. Right Now? Before you consider Fresenius SE & Co., you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE & Co. wasn't on the list. While Fresenius SE & Co. currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [FSNUY.US](https://longbridge.com/en/quote/FSNUY.US.md) - [FRE.DE](https://longbridge.com/en/quote/FRE.DE.md) - [MS.US](https://longbridge.com/en/quote/MS.US.md) - [MSFT.US](https://longbridge.com/en/quote/MSFT.US.md) - [OpenAI.NA](https://longbridge.com/en/quote/OpenAI.NA.md) - [DAL.US](https://longbridge.com/en/quote/DAL.US.md) - [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md) ## Related News & Research - [Fresenius Kabi vedolizumab biosimilar PB016 accepted for FDA, EMA review](https://longbridge.com/en/news/294465104.md) - [Fresenius names Thomas Thestrup head of new Ventures unit](https://longbridge.com/en/news/293578816.md) - [Fuchs SE GAAP EPS of €1.36, revenue of €2B](https://longbridge.com/en/news/294513864.md) - [Fresenius establishes venture fund of more than €200 million to drive healthcare innovation | FSNUY Stock News](https://longbridge.com/en/news/293588612.md) - [Deutsche Bank Reaffirms Their Buy Rating on Fresenius SE & Co. KGaA (0OO9)](https://longbridge.com/en/news/293183874.md)